Zacks Small Cap Has Positive Outlook of QNRX FY2025 Earnings

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Research analysts at Zacks Small Cap upped their FY2025 earnings per share estimates for Quoin Pharmaceuticals in a research note issued on Monday, March 17th. Zacks Small Cap analyst M. Marin now anticipates that the company will earn ($0.44) per share for the year, up from their prior estimate of ($2.00). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share.

Quoin Pharmaceuticals Price Performance

Quoin Pharmaceuticals stock opened at $0.30 on Thursday. Quoin Pharmaceuticals has a one year low of $0.27 and a one year high of $1.57. The stock has a market capitalization of $1.51 million, a PE ratio of -0.07 and a beta of 1.82. The business’s fifty day moving average is $0.37 and its 200 day moving average is $0.55.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.15.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of QNRX. Altium Capital Management LLC bought a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $184,000. Renaissance Technologies LLC lifted its holdings in Quoin Pharmaceuticals by 244.1% in the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after acquiring an additional 94,431 shares during the period. Boothbay Fund Management LLC bought a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $53,000. Finally, Apollon Wealth Management LLC bought a new position in shares of Quoin Pharmaceuticals in the fourth quarter worth about $52,000. Institutional investors own 8.63% of the company’s stock.

Insider Activity at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, COO Denise P. Carter acquired 555,556 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average cost of $0.45 per share, with a total value of $250,000.20. Following the completion of the transaction, the chief operating officer now directly owns 602,648 shares of the company’s stock, valued at approximately $271,191.60. This represents a 1,179.72 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Gordon Dunn bought 122,221 shares of the stock in a transaction on Monday, December 23rd. The stock was purchased at an average cost of $0.45 per share, for a total transaction of $54,999.45. Following the acquisition, the chief financial officer now owns 151,077 shares of the company’s stock, valued at $67,984.65. This trade represents a 423.55 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 777,777 shares of company stock valued at $350,000 over the last ninety days. Insiders own 3.70% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.